Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Ocugen (OCGN) announced that dosing is complete, ahead of schedule in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410-a ...

Carrier Transicold has introduced the second generation of its fully electric Vector eCool trailer refrigeration unit (TRU), ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

Q4 2024 Earnings Conference Call February 14, 2025 3:00 AM ETCompany ParticipantsMasamichi Terabatake - Group President ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

But after finishing Starward Vector I couldn’t shake the desire ... opening up storylines and the rewards and trials that come with them. Not only are there more activities to take part in ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's results. Click for this VYGR update.

CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.